scispace - formally typeset
Open AccessJournal ArticleDOI

Dendritic cell-based immunotherapy

TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.
Abstract
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Photothermal-Activatable Fe3O4 Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy

TL;DR: Findings suggest that Fe3O4-R837 SP-involved PTT can significantly potentiate the systemic therapeutic efficiency of PD-L1 checkpoint blockade therapy by activating both innate and adaptive immune systems in the body.
Journal ArticleDOI

Antitumor effects of immunity-enhancing traditional Chinese medicine.

TL;DR: This review will summarize research progress of antitumor TCM that regulates the immune system, including both innate immunity, such as macrophages, dendritic cells, natural killer cells and MDSCs, and adaptive immunity, including CD4+/CD8+ T lymphocytes, regulatory T cells (Tregs) and B cells.
Journal ArticleDOI

Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity

TL;DR: A DC differentiation method from human CD34+ precursors leading to high yields of plasmacytoid DCs and both types of conventional DCs, and a pre-terminal differentiation state for each DC type is discovered, characterized by high expression of cell-cycle genes and lack of XCR1 in the case of cDC1.
Journal ArticleDOI

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.

TL;DR: With the success of immune checkpoint inhibition in several malignancies and considering the plethora of other treatment modalities being developed, it is of utmost importance to delineate the position of dendritic cell therapy in the treatment landscape of cancer.
Journal ArticleDOI

Trial watch: Dendritic cell-based anticancer immunotherapy.

TL;DR: This Trial Watch surveys the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics and highlights how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche within the wide cancer immunotherapy landscape.
References
More filters
Journal ArticleDOI

Toll-like receptor signalling

TL;DR: Rapid progress that has recently improved the understanding of the molecular mechanisms that mediate TLR signalling is reviewed.
Journal ArticleDOI

Immunobiology of Dendritic Cells

TL;DR: Dendritic cells are antigen-presenting cells with a unique ability to induce primary immune responses and may be important for the induction of immunological tolerance, as well as for the regulation of the type of T cell-mediated immune response.
Journal ArticleDOI

Neoantigens in cancer immunotherapy

TL;DR: Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Related Papers (5)